The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains

By afschroeder • July 29, 2026

Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, Armstrong AW, Gottlieb AB, Han G, Khattri S, Shaigany S, Weinberg JM, Lebwohl M. The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains. Dermatol Online J. 2026 May 8;32(2). doi: 10.25251/zsav4a48. PMID: 42522480.

Tags: Biologics, Dermatology, IL-17 inhibitors, IL-23 inhibitors, PsA, psoriasis, psoriatic arthritis, Publications

Related Posts

A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel

Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, Armstrong A, Boh E, Gottlieb AB, Khattri S, Litchman G, Merola J, Murina[...]

Vitiligo in the United States: A 10-year study of patient characteristics, comorbidities, and treatment patterns

Huang MY, Smart K, Lee K, Kingston P, Yee D, Peterson H, Korouri E, Armstrong AW. Vitiligo in the United States: A 10-year study of[...]

The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel

DeBusk L, Bartley B, Armstrong AW, Bunick CG, Del Rosso J, Desai SR, Eichenfield LF, Elewski BE, Golant AK, Issa N, Stein Gold L, Swanson[...]